Zobrazeno 1 - 10
of 164
pro vyhledávání: '"Kristina Callis Duffin"'
Autor:
Bruce Strober, Kristina Callis Duffin, Mark Lebwohl, Adam Sima, Jud Janak, Manish Patel, Huzefa Photowala, Vishvas Garg, Jerry Bagel
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
AbstractBackground The impact of psoriasis in special areas (i.e., scalp, nails, palms, soles, genitals) on patient physical functioning, health-related quality of life (HRQoL), and work abilities has not been fully characterized. We assessed associa
Externí odkaz:
https://doaj.org/article/1b0eb84475ce4aa5a48cca6c2ff2e91c
Publikováno v:
JAAD Case Reports, Vol 3, Iss 5, Pp 432-435 (2017)
Externí odkaz:
https://doaj.org/article/7b9820930c0947908ab6c8ba51076e26
Autor:
Lam C. Tsoi, Philip E. Stuart, Chao Tian, Johann E. Gudjonsson, Sayantan Das, Matthew Zawistowski, Eva Ellinghaus, Jonathan N. Barker, Vinod Chandran, Nick Dand, Kristina Callis Duffin, Charlotta Enerbäck, Tõnu Esko, Andre Franke, Dafna D. Gladman, Per Hoffmann, Külli Kingo, Sulev Kõks, Gerald G. Krueger, Henry W. Lim, Andres Metspalu, Ulrich Mrowietz, Sören Mucha, Proton Rahman, Andre Reis, Trilokraj Tejasvi, Richard Trembath, John J. Voorhees, Stephan Weidinger, Michael Weichenthal, Xiaoquan Wen, Nicholas Eriksson, Hyun M. Kang, David A. Hinds, Rajan P. Nair, Gonçalo R. Abecasis, James T Elder
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-8 (2017)
Psoriasis is an immune-mediated skin disease with a complex genetic architecture. Here, Elder and colleagues identify 16 novel psoriasis susceptibility loci using GWAS meta-analysis with a combined effective sample size of over 39,000 individuals.
Externí odkaz:
https://doaj.org/article/f7c9d14db1d44c6a865877ade1d17933
Autor:
April W. Armstrong, Timothy Fitzgerald, Robert R. McLean, Amanda Teeple, Jonathan P. Uy, Mobolaji Olurinde, Katelyn Rowland, Lin Guo, Ying Shan, Kristina Callis Duffin
Publikováno v:
Advances in Therapy. 40:2493-2508
Autor:
Linda Stein Gold, Kim Papp, David Pariser, Neal Bhatia, Howard Sofen, Lorne Albrecht, Melinda Gooderham, Kristina Callis Duffin, Mindy Chen, Maria Paris, Sue Cheng, Hernan Picard, Yao Wang, Lawrence Green
Publikováno v:
Journal of the American Academy of Dermatology. 88:430-433
Publikováno v:
Journal of the American Academy of Dermatology. 88:1119-1121
Autor:
Margo J. Reeder, Joseph F. Merola, Kristina Callis Duffin, Robert A. Swerlick, Vanina Taliercio, Alice B. Gottlieb, Marta J. Van Beek, Lourdes M. Perez-Chada
Publikováno v:
Journal of the American Academy of Dermatology. 88:86-93
International Dermatology Outcome Measures and the American Academy of Dermatology recently agreed on a physician-reported global severity measure to demonstrate quality of care in inflammatory dermatoses.Because patient-reported outcome measures are
Autor:
April W. Armstrong, Timothy Fitzgerald, Robert R. McLean, Amanda Teeple, Jonathan P. Uy, Mobolaji Olurinde, Katelyn Rowland, Lin Guo, Ying Shan, Kristina Callis Duffin
Publikováno v:
Dermatology and Therapy. 13:487-504
In clinical trials, treatment with the interleukin-23 inhibitor guselkumab was associated with significantly improved disease severity and patient-reported outcome measures (PROMs) among patients with moderate-to-severe plaque psoriasis. However, lim
Autor:
A David Burden, Hervé Bachelez, Siew Eng Choon, Slaheddine Marrakchi, Tsen-Fang Tsai, Hamida Turki, Akimichi Morita, Mark G Lebwohl, Robert Bissonnette, Min Zheng, Milan J Anadkat, Alexander A Navarini, Ming Tang, Christian Thoma, Kristina Callis Duffin
Publikováno v:
British Journal of Dermatology.
Generalized pustular psoriasis (GPP), a rare and potentially life-threatening neutrophilic skin disease, is characterized by recurrent flares of pustulation on nonacral skin with associated erythema, crusting and scaling. There are no agreed or valid
Autor:
Yao Wang, Lawrence Green, Howard Sofen, David M. Pariser, Lorne Albrecht, Kim A. Papp, Kristina Callis Duffin, Melinda Gooderham, Linda Stein Gold, Maria Paris, Neal Bhatia, M. Chen
Publikováno v:
Journal of the American Academy of Dermatology. 86:77-85
Patients with mild-to-moderate psoriasis may have substantial quality-of-life impairment.To evaluate apremilast 30 mg twice daily for mild-to-moderate psoriasis.Phase 3, double-blind, placebo-controlled study in adults with mild-to-moderate psoriasis